个性化加速起搏对射血分数保留心衰患者生活质量、体力活动与房颤的影响:myPACE随机临床试验
本研究为盲法随机临床试验,纳入107例B/C期射血分数保留心衰(HFpEF)且已植入起搏器患者,比较个性化加速备用起搏频率与常规60次/分。随访1年,个性化加速起搏组明尼苏达心衰生活质量问卷评分改善,NT-proBNP水平、体力活动及设备检测房颤均优于常规组,不良临床事件较少。
要点
- 个性化加速起搏可改善HFpEF起搏器患者的生活质量与体力活动。
- 该策略降低NT-proBNP水平并减少设备检测的房颤发生。
- 个性化加速起搏在1年随访中安全性良好。
核心结论
- 在HFpEF且植入起搏器患者中,适度加速的个性化起搏频率安全,并较常规60次/分设置改善生活质量、NT-proBNP水平、体力活动和房颤。
研究设计与样本
- 盲法随机临床试验,纳入佛蒙特大学医学中心起搏器门诊2019年6月至2020年11月的B期和C期HFpEF患者,共107例随机分配至个性化加速起搏组(n=50)或常规治疗组(n=57),随访1年,采用改良意向性分析。
主要发现
- 1年随访中,个性化加速起搏组起搏器检测心率中位数(IQR)为75(75-80)次/分,常规治疗组为65(63-68)次/分。
- 个性化加速起搏组MLHFQ评分从基线中位数(IQR)26(8-45)降至1个月15(2-25)、1年9(4-21),P<.001;常规治疗组从基线19(6-42)升至1个月23(5-39)、1年27(7-52),P=.03。
- 个性化加速起搏组NT-proBNP平均(SD)下降109(498)pg/dL,常规治疗组升高128(537)pg/dL,P=.02。
- 个性化加速起搏组体力活动平均(SD)增加47(67)分钟/天,常规治疗组减少22(35)分钟/天,P<.001。
- 设备检测房颤相对风险降低27%(P=.04);不良临床事件在个性化加速起搏组发生4例,常规治疗组11例。
临床怎么用
- 对于已植入起搏器的HFpEF患者,可考虑采用基于身高和射血分数计算的个性化加速备用起搏频率,而非常规60次/分设置。
局限性
- 研究为单中心试验,样本量107例,结果外推需谨慎。
- 随访时间仅1年,长期获益与安全性未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with heart failure with preserved ejection fraction (HFpEF) with a pacemaker may benefit from a higher, more physiologic backup heart rate than the nominal 60 beats per minute (bpm) setting. OBJECTIVE: To assess the effects of a moderately accelerated personalized backup heart rate compared with 60 bpm (usual care) in patients with preexisting pacemaker systems that limit pacemaker-mediated dyssynchrony. DESIGN, SETTING, AND PARTICIPANTS: This blinded randomized clinical trial enrolled patients with stage B and C HFpEF from the University of Vermont Medical Center pacemaker clinic between June 2019 and November 2020. Analysis was modified intention to treat. INTERVENTIONS: Participants were randomly assigned to personalized accelerated pacing or usual care and were followed up for 1 year. The personalized accelerated pacing heart rate was calculated using a resting heart rate algorithm based on height and modified by ejection fraction. MAIN OUTCOMES AND MEASURES: The primary outcome was the serial change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score. Secondary end points were changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, pacemaker-detected physical activity, atrial fibrillation from baseline, and adverse clinical events. RESULTS: Overall, 107 participants were randomly assigned to the personalized accelerated pacing (n = 50) or usual care (n = 57) groups. The median (IQR) age was 75 (69-81) years, and 48 (48%) were female. Over 1-year follow-up, the median (IQR) pacemaker-detected heart rate was 75 (75-80) bpm in the personalized accelerated pacing arm and 65 (63-68) bpm in usual care. MLHFQ scores improved in the personalized accelerated pacing group (median [IQR] baseline MLHFQ score, 26 [8-45]; at 1 month, 15 [2-25]; at 1 year, 9 [4-21]; P < .001) and worsened with usual care (median [IQR] baseline MLHFQ score, 19 [6-42]; at 1 month, 23 [5-39]; at 1 year, 27 [7-52]; P = .03). In addition, personalized accelerated pacing led to improved changes in NT-proBNP levels (mean [SD] decrease of 109 [498] pg/dL vs increase of 128 [537] pg/dL with usual care; P = .02), activity levels (mean [SD], +47 [67] minutes per day vs -22 [35] minutes per day with usual care; P < .001), and device-detected atrial fibrillation (27% relative risk reduction compared with usual care; P = .04) over 1-year of follow-up. Adverse clinical events occurred in 4 patients in the personalized accelerated pacing group and 11 patients in usual care. CONCLUSIONS AND RELEVANCE: In this study, among patients with HFpEF and pacemakers, treatment with a moderately accelerated, personalized pacing rate was safe and improved quality of life, NT-proBNP levels, physical activity, and atrial fibrillation compared with the usual 60 bpm setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04721314.
引用
- Infeld, Wahlberg, Cicero, et al. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36723919. doi:10.1001/jamacardio.2022.5320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。